CLOVIS ONCOLOGY INC's ticker is and the CUSIP is 189464AC4. A total of 33 filers reported holding CLOVIS ONCOLOGY INC in Q3 2018. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2019 | $105,000 | -31.8% | 250,000 | 0.0% | 0.00% | – |
Q2 2019 | $154,000 | -21.0% | 250,000 | 0.0% | 0.00% | – |
Q1 2019 | $195,000 | +10.2% | 250,000 | 0.0% | 0.00% | – |
Q4 2018 | $177,000 | -8.8% | 250,000 | 0.0% | 0.00% | – |
Q3 2018 | $194,000 | -15.7% | 250,000 | 0.0% | 0.00% | – |
Q2 2018 | $230,000 | – | 250,000 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Antara Capital LP | 55,678,000 | $42,628,000 | 3.59% |
HIGHBRIDGE CAPITAL MANAGEMENT LLC | 30,066,000 | $22,875,000 | 0.91% |
OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) | 29,000,000 | $21,750,000,000 | 0.31% |
FARALLON CAPITAL MANAGEMENT LLC | 51,910,000 | $39,243,000 | 0.20% |
OAKTREE CAPITAL MANAGEMENT LP | 6,349,000 | $4,860,000 | 0.07% |
Psagot Value Holdings Ltd. | 1,500,000 | $1,141,000 | 0.03% |
Allianz Asset Management GmbH | 29,945,000 | $22,766,000 | 0.02% |
D. E. Shaw & Co., Inc. | 25,050,000 | $19,155,000 | 0.02% |
AMERIPRISE FINANCIAL INC | 42,200,000 | $31,887,000 | 0.01% |
PALISADE CAPITAL MANAGEMENT, LP | 330,000 | $250,000 | 0.01% |